world-mental-health-2018-scientifictracks

7 / 19

Page 26
Notes:
conferenceseries.com
Volume 20 International Journal of Emergency Mental Health & Human Resilience World Mental Health 2018
July 16-18, 2018
July 16-18, 2018 Dubai, UAE
Public Mental Health and Neuroscience
29th International Conference on
Efficacy and safety of Buspirone in patients with Autism Spectrum Disorder: A systematic review and
meta-analysis
Sami Salahia
Ain Shams University, Egypt
Introduction: Autism Spectrum Disorder is considered one of the most serious developmental disorders that affecting social
interactions and communication. However, around 1 out of 160 children are diagnosed with Autism. Hypothesis suggest
variety of genes play a role in the etiologic of this disorder. Previous trials tried to use Buspirone as a partial serotonin
5-HT(1A) receptors agonist and dopamine D2 auto receptors antagonist in management motor disorder that’s association with
Autism. Our aim from this systematic review and meta-analysis is to assess the Safety and Efficacy of Buspirone compared to
Risperidone or Placebo in management ASD. To systematically review and conduct a meta-analysis of randomized controlled
trials investigating the impact of Losartan as Angiotensin receptor blocker on Hypertrophic Cardiomyopathy Methods: We
searched on PubMed, MEDLINE in Process, Scopus and Web of Science (previously ISI) for relevant studies, published up to
December 2017. We included randomized controlled trials (RCTs) that comparing buspirone 2.5 mg or 5 mg with Risperidone
or Placebo. Data were pooled as risk ratios (RR) or mean differences (MD) with their 95% confidence intervals (CI) between
compared groups in a fixed meta-analysis model. Results: From a total of 122 entries identified, 4 RCTs were appropriate for
inclusion into the final analysis. Regarding efficacy outcomes, 2.5mg Buspirone shows statistically significant over placebo
in terms of Irritability Scale (MD = -0.17, 95% CI [-0.22, -0.12]) and on Inappropriate speech Scale (MD= -0.40, 95% CI
[-0.66, 0.14]) while no significant difference was detected between 2.5mg Buspirone and Placebo. However, 5mg Buspirone
showed a statistically significant over placebo in terms of Inappropriate speech Scale (MD= -0.30 95% CI [-0.55, -0.05]).
On the other hand, The pooled effect size favored placebo over Buspirone in terms of Irritability Scale (MD= 0.14, 95% CI
[0.09, 0.20]), and Social withdrawal (MD= 2.00 ,2.00, 95% CI 1.40, 2.60]). No significant difference was detected between
Buspirone and Risperidone in term of Irritability (MD= 1.85, 95% CI [-3.12, 6.82]). However, overall evidence was insufficient
to suggest a statistically significant difference in the adverse event profile while adequate reporting of adverse events data in
future randomized trials of Buspirone is crucial to conclusively judge its safety.
Conclusion: Our findings showed that Buspirone is more Effective in patients with Autism compared to Risperidone or
Placebo. No significant difference was observed for adverse events among ASD patients. Further trials are required to clarify
the Safety of Buspirone for the treatment of Autism.
Biography
Sami Salahia is co-founder at MRSA Group and Genome Medical Research Association in the UAE. He is a 5th year medical student (Candidate medical Doctor)
at Ain Shams University in Egypt with an interest in medical research and have a number of publications in peer reviewed journals. Being a Team Leader, he gives
training workshops to Undergraduate Medical Students in Egypt and the UAE Specially for Secondary Research.
Sami Salahia, Int J Emerg Ment Health 2018, Volume 20
DOI: 10.4172/1522-4821-C2-014